AKT1 and in situ carcinoma: QUE pre-treatment of Tca-8113 and SCC-15 OSCC lines enhanced CIS cytotoxicity by inhibiting AKT and IKKβ phosphorylation, the NF-κB pathway, and expression of the anti-apoptotic protein xIAP (61).